BioPharm America™ 2017: Xontogeny fills unique niche in biotech market

Chris Garabedian is the chairman and CEO of Boston-based Xontogeny. It calls itself a 'biotech aggregator,' which is one way to describe the process of bringing scientific entrepreneurs, ideas, and capital together into fledgling biotech companies. Speaking at BioPharm America™ in Boston, Garabedian described the niche he sees for Xontogeny in the market, and why it's often overlooked by traditional venture capital.